Skip to content

Nasdaq · CIK 0001411690

BNGO Bionano Genomics, Inc.

Insider trading from SEC Form 4. Last filing 33 d ago. Close $1.44 on Oct 9, 2026, +36% from the 52-week low and -32% from the high.

Last 90 days

Net insider value
+$4,845
more bought than sold
Buys
1
$4,845 by 1 insider
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company

Price and insider trades, last year

BNGOOct 9, 2026 · close 1.44

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Bionano Genomics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
35WeakAlbert Luderer
Interim Chief Executive
buy
$4,845
4,000 shares
+100%-

Transactions

The last 37 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 4, 2026Albert Luderer
Interim Chief Executive
POpen-market purchase
Common Stockindirect: Traditional IRA
+4,000$1.21$4,8458,00033 d ago
Feb 17, 2026Mark Adamchak
Principal Accounting Officer
FTax withholding
Common Stock
-3$1.10$3260Feb 18, 2026
Feb 17, 2026Jonathan V. Dixon
GENERAL COUNSEL
FTax withholding
Common Stock
-6$1.10$7263Feb 18, 2026
Feb 17, 2026Alka Chaubey
CHIEF MEDICAL OFFICER
FTax withholding
Common Stock
-18$1.10$20644Feb 18, 2026
Feb 17, 2026Mark Oldakowski
CHIEF OPERATING OFFICER
FTax withholding
Common Stock
-20$1.10$22895Feb 18, 2026
Feb 17, 2026R. Erik Holmlin
PRESIDENT AND CEO
FTax withholding
Common Stock
-51$1.10$561,657Feb 18, 2026
Feb 2, 2026Mark Adamchak
Principal Accounting Officer
AGrant or award
Stock Option (Right to Buy)derivative
+10,890$0.00$010,890Feb 4, 2026
Feb 2, 2026R. Erik Holmlin
PRESIDENT AND CEO
AGrant or award
Stock Option (Right to Buy)derivative
+69,484$0.00$069,484Feb 4, 2026
Feb 2, 2026Mark Oldakowski
CHIEF OPERATING OFFICER
AGrant or award
Stock Option (Right to Buy)derivative
+27,737$0.00$027,737Feb 4, 2026
Feb 2, 2026Alka Chaubey
CHIEF MEDICAL OFFICER
AGrant or award
Stock Option (Right to Buy)derivative
+27,737$0.00$027,737Feb 4, 2026
Feb 2, 2026Jonathan V. Dixon
GENERAL COUNSEL
AGrant or award
Stock Option (Right to Buy)derivative
+26,117$0.00$026,117Feb 4, 2026
Sep 11, 2025Mark Oldakowski
Chief Operating Officer
FTax withholding
Common Stock
-59$4.06$240915Sep 12, 2025
Sep 11, 2025Alka Chaubey
Chief Medical Officer
FTax withholding
Common Stock
-51$4.06$207662Sep 12, 2025
Sep 11, 2025Mark Oldakowski
Chief Operating Officer
FTax withholding
Common Stock
-59$4.06$240915Sep 12, 2025
Jun 11, 2025Christopher J Twomey
director
AGrant or award
Stock Option (Right to Buy)derivative
+2,775$0.00$02,775Jun 12, 2025
Jun 11, 2025Kristiina Vuori MD
director
AGrant or award
Stock Option (Right to Buy)derivative
+2,775$0.00$02,775Jun 12, 2025
Jun 11, 2025Yvonne Linney
director
AGrant or award
Stock Option (Right to Buy)derivative
+2,775$0.00$02,775Jun 12, 2025
Jun 11, 2025Hannah Mamuszka
director
AGrant or award
Stock Option (Right to Buy)derivative
+2,775$0.00$02,775Jun 12, 2025
Jun 11, 2025Aleksandar Rajkovic
director
AGrant or award
Stock Option (Right to Buy)derivative
+2,775$0.00$02,775Jun 12, 2025
Jun 11, 2025David L Barker
director
AGrant or award
Stock Option (Right to Buy)derivative
+2,775$0.00$02,775Jun 12, 2025
Jun 11, 2025Albert Luderer
Interim Chief Executive
AGrant or award
Stock Option (Right to Buy)derivative
+2,775$0.00$02,775Jun 12, 2025
Jun 3, 2025Mark Adamchak
Principal Accounting Officer
FTax withholding
Common Stock
-7$3.69$26263Jun 3, 2025
Jun 3, 2025Jonathan V. Dixon
General Counsel
FTax withholding
Common Stock
-25$3.69$92269Jun 3, 2025
Jun 3, 2025R. Erik Holmlin
President and CEO
FTax withholding
Common Stock
-75$3.69$2771,708Jun 3, 2025
Jun 3, 2025Alka Chaubey
Chief Medical Officer
FTax withholding
Common Stock
-24$3.69$89713Jun 3, 2025
Jun 3, 2025Mark Oldakowski
Chief Operating Officer
FTax withholding
Common Stock
-27$3.69$100974Jun 3, 2025
Mar 14, 2025Alka Chaubey
Chief Medical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+6,966$0.00$06,966Mar 18, 2025
Mar 14, 2025Jonathan V. Dixon
General Counsel
AGrant or award
Stock Option (Right to Buy)derivative
+6,559$0.00$06,559Mar 18, 2025
Mar 14, 2025R. Erik Holmlin
President and CEO
FTax withholding
Common Stock
-198$3.47$6871,783Mar 18, 2025
Mar 14, 2025Mark Oldakowski
Chief Operating Officer
AGrant or award
Stock Option (Right to Buy)derivative
+6,966$0.00$06,966Mar 18, 2025
Mar 14, 2025Mark Adamchak
Principal Accounting Officer
AGrant or award
Stock Option (Right to Buy)derivative
+3,029$0.00$03,029Mar 18, 2025
Mar 14, 2025R. Erik Holmlin
President and CEO
AGrant or award
Stock Option (Right to Buy)derivative
+17,449$0.00$017,449Mar 18, 2025
Feb 15, 2025Mark Adamchak
Principal Accounting Officer
FTax withholding
Common Stock
-4$5.73$23270Feb 19, 2025
Feb 15, 2025Alka Chaubey
Chief Medical Officer
FTax withholding
Common Stock
-18$5.73$103737Feb 19, 2025
Feb 15, 2025R. Erik Holmlin
President and CEO
FTax withholding
Common Stock
-51$5.73$2921,981Feb 19, 2025
Feb 15, 2025Jonathan V. Dixon
General Counsel
FTax withholding
Common Stock
-6$5.73$34294Feb 19, 2025
Feb 15, 2025Mark Oldakowski
Chief Operating Officer
FTax withholding
Common Stock
-20$5.73$1151,001Feb 19, 2025

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

BNGO insider trading: Bionano Genomics, Inc. | InsiderTell